SEC Tracker
Get the app

BioMarin Pharmaceutical BMRN

Biomarin Pharmaceutical reported strong Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Third quarter 2026 total revenues increased 32% Y/Y to $1.025 billion
  2. Metabolic conditions revenue grew 44% Y/Y in Q3 2026
  3. VOXZOGO revenue grew 12% Y/Y in Q3 2026
  4. BioMarin updated full-year 2026 guidance due to order timing uncertainty

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when BioMarin Pharmaceutical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  4. Repligen RGEN public float $6.0B, Jun 30, 2025
  5. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025